OMERS ADMINISTRATION Corp Grows Holdings in Pfizer Inc. $PFE

OMERS ADMINISTRATION Corp raised its holdings in shares of Pfizer Inc. (NYSE:PFE) by 9.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 307,296 shares of the biopharmaceutical company’s stock after purchasing an additional 25,362 shares during the quarter. OMERS ADMINISTRATION Corp’s holdings in Pfizer were worth $8,629,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Bradley Foster & Sargent Inc. CT increased its position in shares of Pfizer by 2.2% during the first quarter. Bradley Foster & Sargent Inc. CT now owns 614,017 shares of the biopharmaceutical company’s stock worth $17,242,000 after acquiring an additional 13,128 shares during the period. Lombard Odier Asset Management Switzerland SA boosted its holdings in shares of Pfizer by 18.6% in the first quarter. Lombard Odier Asset Management Switzerland SA now owns 219,693 shares of the biopharmaceutical company’s stock valued at $6,169,000 after purchasing an additional 34,500 shares during the period. Waverly Advisors LLC grew its stake in Pfizer by 6.9% in the first quarter. Waverly Advisors LLC now owns 449,282 shares of the biopharmaceutical company’s stock worth $12,616,000 after purchasing an additional 29,015 shares in the last quarter. Asset Management Group Inc. increased its holdings in Pfizer by 6.0% during the 1st quarter. Asset Management Group Inc. now owns 47,678 shares of the biopharmaceutical company’s stock worth $1,339,000 after purchasing an additional 2,697 shares during the period. Finally, Cumberland Partners Ltd increased its holdings in Pfizer by 46.9% during the 1st quarter. Cumberland Partners Ltd now owns 191,855 shares of the biopharmaceutical company’s stock worth $5,387,000 after purchasing an additional 61,285 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on PFE shares. JPMorgan Chase & Co. decreased their target price on Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a research report on Wednesday, July 8th. Wolfe Research reissued an “underperform” rating and set a $26.00 price target on shares of Pfizer in a research report on Thursday, May 14th. Royal Bank Of Canada upgraded Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price target on the stock in a research note on Tuesday, June 9th. Citigroup lifted their price objective on Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a report on Wednesday, April 29th. Finally, Morgan Stanley upped their price objective on shares of Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a research note on Friday, April 10th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Pfizer currently has a consensus rating of “Hold” and an average target price of $28.50.

Pfizer Stock Performance

Shares of PFE opened at $24.52 on Monday. Pfizer Inc. has a 12 month low of $23.11 and a 12 month high of $28.75. The stock has a fifty day moving average price of $25.11 and a 200-day moving average price of $26.17. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. The firm has a market cap of $139.78 billion, a PE ratio of 18.72 and a beta of 0.35.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. During the same period in the previous year, the business earned $0.92 EPS. The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts predict that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.0%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is currently 131.30%.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer announced that PF-08057418 cleared a Phase 1 safety milestone, which helps reinforce confidence in the company’s research pipeline and early-stage development prospects. Article: Pfizer’s PF-08057418 Clears Phase 1 Safety Milestone, Offering a Quiet Boost to Pipeline Confidence
• Positive Sentiment: Pfizer is advancing PF-08653945 into an early-stage obesity trial, giving investors another potential growth driver in a large and competitive therapeutic market. Article: Pfizer Advances New Obesity Shot With Early Stage Trial of PF-08653945
• Positive Sentiment: The FDA granted Priority Review to Pfizer’s Talzenna plus Xtandi regimen for metastatic prostate cancer, which improves the odds of a faster regulatory decision and supports oncology revenue upside if approved. Article: FDA Grants Priority Review for Pfizer’s TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer
• Neutral Sentiment: Unusual call option activity suggests traders are positioning for a move in Pfizer shares, but it does not by itself confirm a fundamental change in the company’s outlook.
• Neutral Sentiment: Recent commentary on Pfizer’s dividend yield and oncology valuation highlights that investors are still weighing income appeal against execution and growth concerns.
• Negative Sentiment: Expanded patent litigation tied to Pfizer’s mRNA vaccine business remains a potential overhang, adding legal and operational uncertainty that could pressure sentiment if the dispute escalates. Article: Pfizer (PFE) Faces Expanded Vaccine Lawsuits On A Fair Value Narrative That Still Sees Upside

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.